We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Molecular Devices

Molecular Devices provides innovative bioanalytical solutions for protein and cell biology in life science research, ... read more Featured Products: More products

Download Mobile App




Immunomarker Found for Recurring HPV-Linked Oropharyngeal Cancers

By LabMedica International staff writers
Posted on 24 Feb 2016
Human papilloma virus (HPV) infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers (OPC) linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk.

People with HPV-positive tumors of the throat, base of the tongue and tonsils have higher overall survival rates compared to people with similar tumors not caused by HPV, but studies show that more than 25% of HPV-positive cancers recur, usually within the first two years after treatment.

Scientists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) designed a retrospective study to determine whether HPV16 antibody titers change after treatment. More...
Participants with HPV-OPC and two or greater serology specimens available were eligible. HPV16 tumor status was obtained from previously reported data which included real time polymerase chain reaction (qPCR) for HPV16 genomic DNA (≥0.1 copy per genome) and high risk HPV in situ hybridization. A subset analysis was restricted to participants with clinically available HPV16-positive in situ hybridization tumor status.

Antibodies to HPV16 E1, E2, E6, and E7 were measured by enzyme-linked immunosorbent assay (ELISA) using the glutathione S-transferase (GST) capture method with some modifications. The ELISA optical density (OD) was measured at 405 nm, with a reference wavelength of 490 nm, in an automated microtiter plate reader (Molecular Devices; Sunnyvale, CA, USA). The mean OD in wells with GST alone was subtracted from the mean OD in wells with the GST-HPV protein to give an antigen-specific OD value.

The team analyzed blood serum samples of 60 patients with HPV-positive oropharyngeal cancer and a median age of 56, mostly Caucasian men. There were 43, 34, and 52 subjects with serum samples available for pretreatment, early, and late posttreatment intervals. Mean pretreatment antibody levels were higher than posttreatment antibody levels. Average antibody levels decreased significantly over time for E6 and E7. Among the 60 patients, they identified six cases of recurring cancer within an average of 4.4 years of follow-up after treatment.

Carole Fakhry, MD, MPH, the lead author of the study, said, “There are currently no reliable tests available to detect early recurrence, so we hope to find a biological marker that could help identify those most at risk. Potentially, a low-risk patient may need less stringent surveillance while a high-risk patient may require more intense imaging.” The study was published online on December 31, 2015, in the journal Cancer Prevention Research.

Related Links:

Johns Hopkins University School of Medicine 
Molecular Devices 



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Chagas Disease Test
LIAISON Chagas
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.